{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:39:54Z","timestamp":1785191994538,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ejogrb.2012.07.023","type":"journal-article","created":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T01:32:01Z","timestamp":1344994321000},"page":"135-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids"],"prefix":"10.1016","volume":"165","author":[{"given":"Vikram Sinai","family":"Talaulikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Manyonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2012.07.023_bib0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.AOG.0000154161.03418.e3","article-title":"Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study","volume":"105","author":"Wise","year":"2005","journal-title":"Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1471-0528.2006.00885.x","article-title":"Long-term follow-up of uterine artery embolisation \u2013 an effective alternative in the treatment of fibroids","volume":"113","author":"Walker","year":"2006","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0015","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/humrep\/12.9.1927","article-title":"Laparoscopic myomectomy: indications, surgical technique and complications","volume":"12","author":"Seinera","year":"1997","journal-title":"Human Reproduction"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0020","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0015-0282(99)00061-8","article-title":"The excision of uterine fibroids by vaginal myomectomy: a prospective study","volume":"71","author":"Davies","year":"1999","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajog.2004.03.037","article-title":"Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multi-centre study","volume":"191","author":"Spies","year":"2004","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2214\/ajr.183.6.01831713","article-title":"MRI guidance of focused ultrasound therapy of uterine fibroids: early results","volume":"183","author":"Hindley","year":"2004","journal-title":"AJR"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1471-0528.2004.00414.x","article-title":"Pregnancy following uterine artery embolisation for symptomatic fibroids: a series of 26 completed pregnancies","volume":"112","author":"Carpenter","year":"2005","journal-title":"BJOG"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0040","unstructured":"National Institute for Clinical Excellence. Guide to the methods of technology appraisal (ref N0515). National Institute for Clinical Excellence UK, April 2004."},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0045","first-page":"20","article-title":"Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue","volume":"55","author":"Wilson","year":"1980","journal-title":"Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/00016348509155136","article-title":"Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium","volume":"64","author":"Tamaya","year":"1985","journal-title":"Acta Gynaecologica Scandinavica"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0055","first-page":"291","article-title":"The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene","volume":"54","author":"Giangrande","year":"1999","journal-title":"Recent Progress in Hormone Research"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0060","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/GCO.0b013e32832e07e8","article-title":"Clinical utility of progesterone receptor modulators and their effect on the endometrium","volume":"21","author":"Spitz","year":"2009","journal-title":"Current Opinion in Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0039-128X(00)00171-9","article-title":"Effects of progesterone on uterine leiomyoma growth and apoptosis","volume":"65","author":"Maruo","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0070","series-title":"The management of menorrhagia in secondary care","author":"Royal College of Obstetricians and Gynaecologists","year":"1999"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004347-198609000-00005","article-title":"Endometrial morphology during long term use of levonorgestrel releasing intra-uterine devices","volume":"5","author":"Silverberg","year":"1986","journal-title":"International Journal of Gynaecological Pathology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0080","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1471-0528.1998.tb10172.x","article-title":"Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia","volume":"105","author":"Irvine","year":"1998","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0085","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/bmj.316.7138.1122","article-title":"Open randomised study of use of levonorgestrel releasing intrauterine system as an alternative to hysterectomy","volume":"316","author":"L\u00e4hteenm\u00e4ki","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(00)03615-1","article-title":"Quality of life and cost effectiveness of levonorgestrel releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial","volume":"357","author":"Hurskainen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0095","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.291.12.1456","article-title":"Clinical outcomes and costs with the levonorgestrel- releasing intrauterine system or hysterectomy for treatment of menorrhagia. Randomised trial 5-year follow up","volume":"291","author":"Hurskainen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0100","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/humrep\/16.10.2103","article-title":"Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium","volume":"16","author":"Maruo","year":"2001","journal-title":"Human Reproduction"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0105","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.contraception.2007.01.025","article-title":"Effects of levonorgestrel-releasing IUS ands progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas","volume":"75","author":"Maruo","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0110","series-title":"Heavy menstrual bleeding: clinical guideline CG 44","author":"National Collaborating Centre for Women's and Children's health","year":"2007"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0115","article-title":"Progesterone and progesterone receptor modulator in uterine leiomyoma growth","author":"Ohara","year":"2008"},{"issue":"8 Suppl","key":"10.1016\/j.ejogrb.2012.07.023_bib0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1933719107311464","article-title":"Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells","volume":"14","author":"Ohara","year":"2007","journal-title":"Reproductive Science"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/molehr\/gan004","article-title":"Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells","volume":"14","author":"Xu","year":"2008","journal-title":"Molecular Human Reproduction"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jsbmb.2010.05.005","article-title":"Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium","volume":"122","author":"Catherino","year":"2010","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-0030-1251483","article-title":"Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth","volume":"28","author":"Yoshida","year":"2010","journal-title":"Seminars in Reproductive Medicine"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0140","doi-asserted-by":"crossref","DOI":"10.1002\/9783527623297.ch7","article-title":"Progesterone receptor antagonists","author":"Spitz","year":"2008"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0145","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy","volume":"93","author":"Wilkens","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0150","article-title":"Progesterone receptor modulators in endometriosis: a new therapeutic option","author":"Spitz","year":"2009"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0155","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","article-title":"Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic\u2013pituitary\u2013ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0160","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/humrep\/deh738","article-title":"The effects of one-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in normal women","volume":"20","author":"Chwalisz","year":"2005","journal-title":"Human Reproduction"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0165","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0170","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2165\/00002018-200225110-00002","article-title":"A benefit-risk assessment of medical treatment for uterine leiomyomas","volume":"25","author":"De Leo","year":"2002","journal-title":"Drug Safety"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0175","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0180","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.fertnstert.2005.05.056","article-title":"Management of patients receiving long term treatment with mifepristone","volume":"84","author":"Spitz","year":"2005","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0185","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of Mifepristone for symptomatic leiomyomata on quality of life and uterine size","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0190","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial","volume":"112","author":"Carbonell Esteve","year":"2008","journal-title":"Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0195","first-page":"17","article-title":"Effects of a new progesterone receptor modulator CDB-4124, on fibroid size and uterine bleeding, US","volume":"3","author":"Wiehle","year":"2008","journal-title":"Obstetrics and Gynecology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ogc.2005.12.011","article-title":"Future directions in myoma research","volume":"33","author":"Brahma","year":"2006","journal-title":"Obstetrics and Gynecology Clinics of North America"},{"issue":"2","key":"10.1016\/j.ejogrb.2012.07.023_bib0205","article-title":"Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867","volume":"10","author":"Chwalisz","year":"2003","journal-title":"Journal of the Society for Gynecologic Investigation"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0210","first-page":"320A","article-title":"Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata","volume":"11","author":"Chwalisz","year":"2004","journal-title":"Journal of the Society for Gynecologic Investigation"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0215","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstetrics and Gynecology"},{"issue":"767-772","key":"10.1016\/j.ejogrb.2012.07.023_bib0220","first-page":"e1","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0225","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"PEARL I Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0235","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/humupd\/dmm023","article-title":"Progesterone receptor modulators and the endometrium: changes and consequences","volume":"13","author":"Horne","year":"2007","journal-title":"Human Reproduction Update"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0240","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Modern Pathology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0245","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata","volume":"22","author":"Williams","year":"2007","journal-title":"Human Reproduction"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0250","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/modpathol.2008.204","article-title":"Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator","volume":"22","author":"Ioffe","year":"2009","journal-title":"Modern Pathology"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0255","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/humrep\/dem177","article-title":"A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)","volume":"22","author":"Lakha","year":"2007","journal-title":"Human Reproduction"},{"key":"10.1016\/j.ejogrb.2012.07.023_bib0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/humrep\/deg022","article-title":"Effect of long-term treatment with low-dose mifepristone on the endometrium","volume":"18","author":"Baird","year":"2003","journal-title":"Human Reproduction"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211512003429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211512003429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:59:53Z","timestamp":1782925193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211512003429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0301211512003429"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2012.07.023","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2012.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ireland Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}